Autopsy report · NCT04512430

Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients

“Low recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 3 years 8 months before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Fundación GECP

Sponsor type

University, hospital or other

Conditions

Non Small Cell Lung Cancer; EGFR Gene Mutation

Interventions

Atezolizumab; Bevacizumab; Carboplatin; Pemetrexed

Participants

4

Sites

18

Countries

Spain

Trials that died the same way

• Impact of Methadone on Prolonged Mechanical Ventilation in Patients on Continuous Treatment With Opioids
  “very low recruitment” (95% match in meaning)
• Study of Psychomotor Development and Attachment in Children Aged 6 to 30 Months With Oral Disorder
  “Recruitment too low” (92% match in meaning)
• Pharmacologically-based Strategies for Opioid Substitution Therapy During Pregnancy
  “poor recruitment” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.